8-K current report · filed Aug 6, 2026

Health Catalyst, Inc. (HCAT) 8-K Current Report: August 6, 2026

Item 1.02Item 2.01Item 2.02Item 7.01Item EX-99.1Item EX-99.2Item EX-99.3HCAT overview

Short answer

Health Catalyst, Inc. (HCAT) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 1.02 (Termination of a Material Definitive Agreement), Item 2.01 (Completion of Acquisition or Disposition of Assets), Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item EX-99.3 (Exhibit EX-99.3). Full repayment of Credit Facility on July 31, 2026 using Disposition proceeds and cash on hand.

Health Catalyst, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.02 · Termination of a Material Definitive Agreement

  • Full repayment of Credit Facility on July 31, 2026 using Disposition proceeds and cash on hand
  • $122.8M initial term loan and $37.1M delayed draw facility principal repaid
  • $3.2M prepayment premium, $548,022 accrued interest, and other fees paid
  • Debt facility terminated ahead of July 16, 2029 maturity, with all related liens released

Item 2.01 · Completion of Acquisition or Disposition of Assets

  • VitalWare divested to Med-Metrix for $147 million base consideration, subject to customary closing adjustments
  • Net proceeds plus cash on hand used to fully prepay and terminate Health Catalyst’s Credit Facility
  • Transaction shifts VitalWare operations out of Health Catalyst and reduces outstanding debt obligations
  • Transition services to Buyer continue for specified periods of up to six months

Item 2.02 · Results of Operations and Financial Condition

  • Health Catalyst reported financial results for the quarter ended June 30, 2026
  • Full results and management commentary available in Exhibit 99.1
  • Disclosure furnished under Item 2.02, limiting Section 18 liability and incorporation by reference

Item 7.01 · Regulation FD Disclosure

  • Health Catalyst completed a disposition with the Buyer, marking a finalized asset or business sale
  • Transaction completion may reshape portfolio focus and future revenue mix
  • Exhibit 99.2 contains the press release with transaction details relevant to valuation and financial impact

Item EX-99.1 · Exhibit EX-99.1

  • Q2 revenue $70.5M, down 13% YoY, reflecting continued contraction despite exceeding company guidance
  • Adjusted EBITDA $9.9M, up 6% YoY, while GAAP net loss remained severe at $40.5M
  • Adjusted gross margin improved to 51% from 50%, led by professional services margin rising to 22% from 18%
  • Cash and equivalents $60.6M plus short-term investments $42.9M, with $151.9M long-term debt still reported
  • Q3 guidance: revenue $55M-$56M and Adjusted EBITDA $0-$0.5M; full-year revenue $246M-$249M and EBITDA $18M-$18.5M

Item EX-99.2 · Exhibit EX-99.2

  • Vitalware sale closed July 31, 2026, delivering $147 million in total cash consideration, subject to customary adjustments
  • Proceeds plus cash on hand fully repaid and terminated the credit facility, eliminating approximately $19 million in annual GAAP interest expense
  • Divestiture sharpens focus on healthcare intelligence products combining client data, AI, proprietary benchmarks, and improvement expertise
  • Strategic platform includes $2.8 billion in documented outcomes across more than 380 client improvement case studies
  • Debt retirement strengthens financial flexibility, but execution risk remains around converting the focused product strategy into growth

Item EX-99.3 · Exhibit EX-99.3

  • VitalWare divestiture generated $147.0M gross proceeds and $145.2M net cash after approximately $1.8M transaction costs
  • Pro forma gain on sale: $65.9M, with no related tax provision due to substantial deferred tax asset valuation allowances
  • Entire $159.9M term loan principal repaid, requiring $166.4M cash including accrued interest and early termination fees
  • Debt extinguishment creates a $9.7M loss, but removes estimated interest expense of $9.4M for six months and $22.1M annually
  • Post-divestiture pro forma revenue falls to $274.3M for 2025, while net loss improves to $112.2M from $178.0M primarily through debt savings and the sale gain

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Health Catalyst, Inc. 8-K filings

Get the next HCAT 8-K as it lands

Follow HCAT for push alerts, or ask the research agent what this filing means.